A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine ...
Many clinicians who treat men with prostate cancer may be unfamiliar with the term "treatment-emergent small-cell neuroendocrine prostate cancer" (t-SCNC). That's because it has been considered a rare ...
A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
Radiosurgery New York (RSNY) Demystifies Kinds of Prostate Cancer for Enhanced Patient Awareness NEW YORK, NY, USA, August 24, 2023/EINPresswire.com/ -- Radiosurgery ...
Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...
If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results